This is a Phase IV prospective, multicenter, observational study to estimate the proportion of subjects 0 to 3 years of age who develop abnormal thyroid function after exposure to intravascular administration of ISOVUE for the required radiologic procedure as part of their standard of care.
Full Title of Study: “A Prospective, Multicenter Observational Study to Evaluate Thyroid Function of Pediatric Subjects From Birth to 3 Years Exposed to ISOVUE® (Iopamidol Injection)”
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Other
- Masking: None (Open Label)
- Study Primary Completion Date: December 1, 2024
- Drug: Isovue
- Isovue will be given to all subjects per the standard of clinical care.
Arms, Groups and Cohorts
- Experimental: ISOVUE
- Isovue will be given to all subjects per the standard of clinical care.The specific iodine concentration and volume of ISOVUE used during the radiologic procedure will depend on the type of procedure and the standards in place at the site where the procedure is performed.
Clinical Trial Outcome Measures
- Abnormal thyroid function
- Time Frame: Day 1 to 2 months
- The primary outcome of this study is to evaluate the proportion of subjects, 0 to 3 years of age, developing abnormal thyroid function after administration of ISOVUE.
- Time Frame: Day 1 to 2 months
- To evaluate the proportion of subjects, 0 to 3 years of age, with hypothyroidism regardless of the need for thyroid hormone therapy after administration of ISOVUE.
- Thyroid hormone replacement therapy
- Time Frame: Day 1 to 12 months
- The proportion of subjects initiated on thyroid hormone replacement therapy.
Participating in This Clinical Trial
- Is male or female from 0 to 3 years of age;
- Is scheduled to undergo a radiologic examination that requires intravascular administration of ISOVUE as part of his/her standard of care;
- Has normal baseline thyroid function tests (TSH, total T3, total T4, and fT4) performed at a local laboratory with blood sample obtained within one week prior to ISOVUE administration;
- Written informed consent is obtained from the subject's parent(s) or legally acceptable representative(s) (according to local regulations) who are willing to comply with the protocol requirements.
- Has any known allergy to one or more of the ingredients of ISOVUE;
- Has been diagnosed with congenital hypothyroidism;
- Has undergone radiation treatments to the head or neck;
- Is currently on thyroid replacement therapy;
- Is on therapy with dopamine or any treatment which may affect the thyroid function testing results;
- Has been exposed to any topical iodinated product within 30 days prior to enrollment in the present study;
- Has been exposed to an iodinated contrast agent within 1 year prior to enrollment in the present study, including any administration of iodinated contrast agents during placement of a central line;
- Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post-dose follow-up examinations.
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: 3 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Bracco Diagnostics, Inc
- Provider of Information About this Clinical Study
- Overall Official(s)
- Mary Luigia Storto, MD, Study Director, Bracco Corporate
- Overall Contact(s)
- Julia Yureneva, MD, 609-514-2554, firstname.lastname@example.org
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.